Gilead Sciences has unveiled plans to make affordable versions of its groundbreaking HIV prevention drug, lenacapavir, available in 120 low and middle-income countries. Lenacapavir, which is administered as a twice-yearly injection, has shown promising results in clinical trials, significantly reducing HIV infection rates among both women and men. In trials conducted in South Africa and…